Westfield Capital Management Co. LP Has $766.52 Million Position in Ascendis Pharma A/S (NASDAQ:ASND)

Westfield Capital Management Co. LP boosted its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 3.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,133,766 shares of the biotechnology company’s stock after acquiring an additional 170,942 shares during the quarter. Ascendis Pharma A/S makes up approximately 3.5% of Westfield Capital Management Co. LP’s holdings, making the stock its 4th biggest holding. Westfield Capital Management Co. LP owned about 8.47% of Ascendis Pharma A/S worth $766,523,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Valence8 US LP bought a new stake in shares of Ascendis Pharma A/S during the third quarter valued at approximately $685,000. Massachusetts Financial Services Co. MA lifted its holdings in Ascendis Pharma A/S by 9.1% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock worth $278,760,000 after buying an additional 155,971 shares in the last quarter. Advisors Asset Management Inc. boosted its position in Ascendis Pharma A/S by 23.2% in the 3rd quarter. Advisors Asset Management Inc. now owns 4,742 shares of the biotechnology company’s stock valued at $708,000 after buying an additional 894 shares during the last quarter. Avior Wealth Management LLC boosted its position in Ascendis Pharma A/S by 3.0% in the 3rd quarter. Avior Wealth Management LLC now owns 8,212 shares of the biotechnology company’s stock valued at $1,226,000 after buying an additional 240 shares during the last quarter. Finally, Thrivent Financial for Lutherans increased its stake in shares of Ascendis Pharma A/S by 0.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company’s stock valued at $11,717,000 after buying an additional 228 shares during the period.

Ascendis Pharma A/S Trading Up 5.8 %

Shares of Ascendis Pharma A/S stock opened at $129.81 on Friday. The stock’s fifty day simple moving average is $133.22 and its 200 day simple moving average is $132.20. The company has a market capitalization of $7.87 billion, a PE ratio of -16.07 and a beta of 0.66. Ascendis Pharma A/S has a 12 month low of $90.13 and a 12 month high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. Analysts predict that Ascendis Pharma A/S will post -7.45 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently issued reports on ASND. StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday. TD Cowen reduced their target price on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Wedbush reiterated an “outperform” rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Bank of America increased their price objective on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Finally, The Goldman Sachs Group lifted their target price on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $191.77.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.